Literature DB >> 12623817

Recovery of visual function in patients with biopsy-proven giant cell arteritis.

Rod Foroozan1, Vincent A Deramo, Lawrence M Buono, D Gerard R Jayamanne, Robert C Sergott, Helen Danesh-Meyer, Peter J Savino.   

Abstract

OBJECTIVE: To assess the visual function of patients with giant cell arteritis (GCA) who had visual loss from either anterior ischemic optic neuropathy (AION) or central retinal artery occlusion and had a subsequent improvement in visual acuity after treatment with corticosteroids.
DESIGN: Retrospective, observational case series. PARTICIPANTS: Thirty-two consecutive patients with biopsy-proven GCA treated at one institution between January 1992 and December 1997. INTERVENTION: Treatment with intravenous methylprednisolone 250 mg every 6 hours for 3 days, followed by oral prednisone 1 mg/kg daily for at least 4 weeks duration. MAIN OUTCOME MEASURES: The number of patients with an improvement in visual acuity after treatment with intravenous methylprednisolone; neuro-ophthalmic evaluation, including visual acuity, funduscopy, and visual field examination of these patients.
RESULTS: Improvement in visual acuity occurred in 5 of 39 eyes (13%) with visual loss from biopsy-proven GCA, and all 5 patients had AION. Despite the improvement of visual acuity in these 5 patients, perimetry revealed marked constriction of the visual field in each affected eye.
CONCLUSIONS: The prognosis for visual improvement in GCA is poor. Although an improvement in visual acuity occurred in 5 of our patients, marked constriction of the visual field was present in all of them.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623817     DOI: 10.1016/S0161-6420(02)01775-X

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 2.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 3.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 4.  Review of Giant cell arteritis.

Authors:  Joseph G Chacko; J Anthony Chacko; Michael W Salter
Journal:  Saudi J Ophthalmol       Date:  2014-11-01

5.  Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E(1) and steroids.

Authors:  Robert D Steigerwalt; M Rosaria Cesarone; Gianni Belcaro; Antonella Pascarella; Mauro De Angelis; Roberto Gattegna; Marcella Nebbioso
Journal:  Int J Angiol       Date:  2010

6.  Treatment of vision loss in giant cell arteritis.

Authors:  Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

7.  Preserved Visual Acuity in Anterior Ischemic Optic Neuropathy Secondary to Giant Cell (temporal) Arteritis.

Authors:  Aileen A Antonio-Santos; Sally J Murad-Kejbou; Rod Foroozan; Sunita Yedavally; David I Kaufman; Eric R Eggenberger
Journal:  J Vasc Interv Neurol       Date:  2016-01

8.  Current diagnosis and treatment of temporal arteritis.

Authors:  Wolfgang A Schmidt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-04

Review 9.  [Vasculitis. Treatment outcome parameters].

Authors:  P M Aries; A Gause
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 10.  Neuro-ophthalmic complications in giant cell arteritis.

Authors:  Frances A Borg; Victoria L J Salter; Bhaskar Dasgupta
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.